Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway

Documenti analoghi

• Novel agents and strategies for overcoming EGFR TKIs resistance
  di: Niu, Fei-Yu, et al.
  Pubblicazione: (2014)
• Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
  di: Wei, Zhigang, et al.
  Pubblicazione: (2017)
• Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-κB Signaling Pathway
  di: Li, Ling, et al.
  Pubblicazione: (2020)
• Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-κB Signaling Pathway
  di: Ling Li, et al.
  Pubblicazione: (2020-09-01)
• Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
  di: Li, Meng-Xia, et al.
  Pubblicazione: (2017)